These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33231774)

  • 1. Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.
    Galarza-Delgado DÁ; Serna-Peña G; Compeán-Villegas JE; Cardenas-de la Garza JA; Pineda-Sic RA; Colunga-Pedraza IJ; Vega-Morales D; Pérez-Barbosa L; Skinner-Taylor CM; Flores-Alvarado DE
    Clin Rheumatol; 2021 Mar; 40(3):1197-1199. PubMed ID: 33231774
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 in Rheumatic Diseases: A Research Agenda.
    Yazdany J
    Arthritis Rheumatol; 2020 Oct; 72(10):1596-1599. PubMed ID: 32705748
    [No Abstract]   [Full Text] [Related]  

  • 3. Rheumatic disease and COVID-19: epidemiology and outcomes.
    Hyrich KL; Machado PM
    Nat Rev Rheumatol; 2021 Feb; 17(2):71-72. PubMed ID: 33339986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases.
    Cook C; Patel NJ; D'Silva KM; Hsu TY; DiIorio M; Prisco L; Martin LW; Vanni K; Zaccardelli A; Todd D; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2022 Feb; 81(2):289-291. PubMed ID: 34489304
    [No Abstract]   [Full Text] [Related]  

  • 5. Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis.
    Hakala M; Immonen K; Korpela M; Vasala M; Kauppi MJ
    Ann Rheum Dis; 2013 Mar; 72(3):464-5. PubMed ID: 23148310
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.
    Bjornsson AH; Grondal G; Kristjansson M; Jonsdottir T; Love TJ; Gudbjornsson B;
    Ann Rheum Dis; 2021 May; 80(5):671-672. PubMed ID: 33402343
    [No Abstract]   [Full Text] [Related]  

  • 7. SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases.
    Lawson-Tovey S; Hyrich KL; Gossec L; Strangfeld A; Carmona L; Raffeiner B; Yardımcı GK; Trefond L; Roux N; Rodrigues A; Papagoras C; Mateus EF; Mariette X; Machado PM
    Ann Rheum Dis; 2022 Jan; 81(1):145-150. PubMed ID: 34489305
    [No Abstract]   [Full Text] [Related]  

  • 8. Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry.
    Glintborg B; Jensen DV; Engel S; Terslev L; Pfeiffer Jensen M; Hendricks O; Ostergaard M; Horskjær Rasmussen S; Adelsten T; Colic A; Danebod K; Kildemand M; Loft AG; Munk HL; Pedersen JK; Østgård RD; Møller Sørensen C; Krogh NS; Agerbo J; Ziegler C; Hetland M
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33402443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.
    Celik S; Kutu ME; Bal C; Karadeniz B; Atagunduz P; Soy M
    Clin Exp Rheumatol; 2023 Mar; 41(3):758-759. PubMed ID: 36226619
    [No Abstract]   [Full Text] [Related]  

  • 10. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
    Erre GL; Ferraccioli ES; Piga M; Mangoni A; Passiu G; Gremese E; Ferraccioli G
    Ann Rheum Dis; 2021 Mar; 80(3):e29. PubMed ID: 32424028
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques
    D'Silva KM; Serling-Boyd N; Wallwork R; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2022 Aug; 81(8):e135. PubMed ID: 32660976
    [No Abstract]   [Full Text] [Related]  

  • 12. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study.
    Di Iorio M; Cook CE; Vanni KMM; Patel NJ; D'Silva KM; Fu X; Wang J; Prisco LC; Kowalski E; Zaccardelli A; Martin LW; Qian G; Hsu TY; Wallace ZS; Sparks JA
    Semin Arthritis Rheum; 2022 Aug; 55():152025. PubMed ID: 35617780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.
    Benucci M; Damiani A; Giannasi G; Li Gobbi F; Quartuccio L; Grossi V; Infantino M; Manfredi M
    Ann Rheum Dis; 2023 Feb; 82(2):e38. PubMed ID: 32632035
    [No Abstract]   [Full Text] [Related]  

  • 14. Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Aydin SZ; Hepworth E; Tugwell P
    Ann Rheum Dis; 2023 Mar; 82(3):e69. PubMed ID: 33355117
    [No Abstract]   [Full Text] [Related]  

  • 15. Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco
    Giollo A; Bertoldo E; Adami G; Cybulski AJ; Fassio A; Orsolini G; Idolazzi L; Gatti D; Viapiana O; Rossini M
    Ann Rheum Dis; 2022 Nov; 81(11):e222. PubMed ID: 32895237
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.
    D'Silva KM; Serling-Boyd N; Hsu TY; Sparks JA; Wallace ZS
    Ann Rheum Dis; 2021 Jun; 80(6):817-819. PubMed ID: 33436385
    [No Abstract]   [Full Text] [Related]  

  • 17. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
    Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
    RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
    Pileggi GS; Ferreira GA; Reis APMG; Reis-Neto ET; Abreu MM; Albuquerque CP; Araújo NC; Bacchiega AB; Bianchi DV; Bica B; Bonfa ED; Borba EF; Brito DCSE; Duarte ÂLBP; Santo RCE; Fernandes PR; Guimarães MP; Gomes KWP; Kakehasi AM; Klumb EM; Lanna CCD; Marques CDL; Monticielo OA; Mota LMH; Munhoz GA; Paiva ES; Pereira HLA; Provenza JR; Ribeiro SLE; Junior LFR; Sampaio CSJC; Sampaio VS; Sato EI; Skare T; de Souza VA; Valim V; Lacerda MVG; Xavier RM; Pinheiro MM
    Adv Rheumatol; 2021 Oct; 61(1):60. PubMed ID: 34620246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
    Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
    Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
    [No Abstract]   [Full Text] [Related]  

  • 20. Laboratory-confirmed pediatric COVID-19 in patients with rheumatic diseases: A case series in a tertiary hospital.
    Ihara BP; Strabelli CA; Simon JR; Viana VS; Sallum AM; Kozu KT; Aikawa NE; Leal GN; Pereira MF; Marques HH; Silva CA; Campos LM
    Lupus; 2021 Apr; 30(5):856-860. PubMed ID: 33653193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.